StockData

Atara Biotherapeutics vs Fate Therapeutics

ATRA and FATE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ATRA and FATE compare

Fate Therapeutics is the larger company, worth 1.9 times as much as Atara Biotherapeutics ($122M against $65.2M).

Fate Therapeutics grew revenue faster over the last twelve months (−23.4% versus −96.7% for Atara Biotherapeutics).

Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −269% compared with −1941% at Fate Therapeutics.

Fate Therapeutics scores higher on the StockData Score (8 against 3 for Atara Biotherapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricATRAFATE
Size and price
Market cap$65.2M$122M
Share price$6.50$1.02
Change, 1 year−52.8%5.8%
Change, 5 years−98.5%−98.1%
Beta (5Y)1.993.98
Employees14161
StockData Score
Total score38 (better)
Valuation score03 (better)
Growth score1 (better)0
Performance score1 (better)0
Health score15 (better)
Dividend score00
Valuation
P/S10.5× (better)18.8×
P/B–0.8×
FCF yield–−86.4%
Fair value–$1.34
Margin of safety–23.8%
Growth
Revenue growth (TTM)−96.7%−23.4% (better)
Revenue growth, 5Y average–−26.7%
Net income growth (TTM)−388%–
Profitability
Operating margin−230% (better)−2058%
Net margin−269% (better)−1941%
FCF margin–−1627%
Return on equity–−60.7%
Return on invested capital–−553%
Financial health
Debt / equity–0.00
Interest coverage−5.0×–
Current ratio1.984.85 (better)
Altman Z-score−136.12−8.99 (better)
Piotroski F-score5 (better)3
Dividends and buybacks
Buyback yield−14.2%–
Shareholder yield−14.2%0.00% (better)
Ownership
Held by institutions44.5%59.9%
Held by insiders55.5%25.7%
Insider net buying, 12 months$2.0M (better)−$336K
Short interest, % of float6.6%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.